Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.67 |
| ▸ | HTR7 | P34969 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27583143 | 0.98 | ADRB2 (0.65) | ADRB2HTR7TP53MAPK1RAB9A | |
| SCHEMBL27301114 | 0.96 | ADRB2 (0.63) | ADRB2HTR7TP53MAPK1RAB9A | |
| SCHEMBL10706756 | 0.90 | ADRB2 (0.65) | ADRB2HTR7TP53MAPK1RAB9A | |
| SCHEMBL7638760 | 0.89 | ADRB2 (0.63) | ADRB2HTR7TP53MAPK1RAB9A | |
| SCHEMBL34465293 | 0.89 | ADRB2 (0.63) | ADRB2HTR7TP53MAPK1RAB9A | |
| SCHEMBL27528318 | 0.88 | ADRB2 (0.54) | ADRB2HTR7TP53MAPK1RAB9A | |
| SCHEMBL13739595 | 0.87 | TP53 (0.74) | ADRB2HTR7TP53MAPK1RAB9A | |
| SCHEMBL10438816 | 0.87 | HTR7 (0.53) | ADRB2HTR7TP53MAPK1RAB9A | |
| SCHEMBL15473193 | 0.87 | ADRB2 (0.53) | ADRB2HTR7TP53MAPK1RAB9A | |
| SCHEMBL10434829 | 0.87 | ADRB2 (0.61) | ADRB2HTR7TP53MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113511987-A | Chiral photosensitive dopant and preparation method and application thereof | 华南师范大学 | 2021-10-19 | — | — | CN | claimed |
| CN-109053387-B | Method for synthesizing magnolol | 九江学院 | 2021-07-09 | — | — | CN | claimed |
| CN-106928283-B | Carbazole and the double modifications of phosphine oxygen are coordinated phenylbenzimidazol complex of iridium, preparation method and applications | 黑龙江大学 | 2019-05-07 | — | — | CN | claimed |
| CN-106928283-A | Carbazole and the double modifications of phosphine oxygen coordination phenylbenzimidazol complex of iridium, preparation method and applications | 黑龙江大学 | 2017-07-07 | — | — | CN | claimed |
| CN-104769000-A | Epoxy resin mixture, epoxy resin composition, and cured product thereof | NIPPON KAYAKU KK | 2015-07-08 | — | — | CN | claimed |
| CN-102648236-A | Anaerobically compostable polymeric compositions, articles and landfill biodegradation | BIOTECH PRODUCTS LLC | 2012-08-22 | — | — | CN | claimed |
| CN-1245382-C | 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORP (KR) | 2006-03-15 | — | — | CN | claimed |
| CN-1568309-A | 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORP (KR) | 2005-01-19 | — | — | CN | claimed |
| US-12516039-B2 | N-linked isoquinoline amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250177408-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Etern Therapeutics Hongkong Limited (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4536356-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Xenon Pharmaceuticals Inc. (CA) | 2025-04-16 | — | — | EP | disclosed |
| US-20240254095-A1 | NMDA Receptor Antagonist and Use Thereof | SYNPHATEC (SHANGHAI) BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-08-01 | — | — | US | disclosed |
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| CN-1245382-C | 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORP (KR) | 2006-03-15 | — | — | CN | disclosed |
| US-20050069357-A1 | Image forming apparatus and process cartridge therefor | RICOH COMPANY, LTD (JP) | 2005-03-31 | — | — | US | disclosed |
| CN-1568309-A | 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORP (KR) | 2005-01-19 | — | — | CN | disclosed |
| US-5561016-A | HAVING PHOTOCONDUCTIVE LAYER CONTAINING CHARGE GENERATING MATERIAL, POLYVINYL BUTYRAL BINDER, CHARGE TRANSPORTING MATERIAL AND BIPHENYL(OR DERIVATIVE) ON ELECTROCONDUCTIVE SUPPORT | RICOH COMPANY, LTD. (JP) | 1996-10-01 | — | — | US | disclosed |
| EP-0141656-B1 | IMPREGNATED CAPACITOR | TORAY INDUSTRIES, INC. (JP) | 1988-06-01 | — | — | EP | disclosed |
| EP-0141656-A1 | Impregnated capacitor | TORAY INDUSTRIES, INC. (JP) | 1985-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254095-A1 | NMDA Receptor Antagonist and Use Thereof | GRIN2B, GRIN1, GRIN3A | ADRB2 365/4885HTR7 378/4885TP53 3024/4885 |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | ADRB2 4139/4885HTR7 4466/4885TP53 6/4885 |
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | ADRB2 4150/4885HTR7 4737/4885TP53 111/4885 |
| US-20250177408-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | YAP1, YES1, TEAD2 | ADRB2 4507/4885HTR7 4268/4885TP53 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.